Roivant Sciences revenue and financials
$35.85Change from previous close: +0.36%Absolute change: +$0.13
In the fiscal year ended March 2026, Roivant Sciences reported revenue of $8.26M (−71.57% year over year). The net loss was $299.77M.
Fiscal year ending in March. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- −71.57%
- FY to Mar 2026 vs FY to Mar 2025
- Net margin
- -3,629.2%
- FY to Mar 2025: -592.0%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | FY to Mar 2026 | FY to Mar 2025 | FY to Mar 2024 | FY to Mar 2023 | FY to Mar 2022 | FY to Mar 2021 |
|---|---|---|---|---|---|---|
| Total revenue | 8.3 | 29.1 | 32.7 | 31.5 | 55.3 | 23.8 |
| Cost of revenue | 1.3 | 0.9 | 1.6 | 3.0 | — | — |
| Gross profit | 7.0 | 28.1 | 31.1 | 28.5 | — | — |
| Selling, general and administrative | 610 | 591 | 416 | 383 | — | — |
| Research and development | 682 | 550 | 440 | 454 | 483 | 237 |
| Operating income | -515 | -1,003 | 4,497 | -907 | -1,352 | -1,071 |
| EBIT | -1,285 | -1,114 | -825 | -809 | — | — |
| EBITDA | -1,282 | -1,100 | -803 | -790 | — | — |
| Interest expense | — | — | 34.8 | 28.0 | 7.0 | 2.8 |
| Pre-tax income | -265 | -682 | 4,568 | -885 | — | — |
| Income tax | 133 | 48.2 | 21.5 | 4.1 | 0.4 | 1.7 |
| Net income | -300 | -172 | 4,349 | -1,009 | -845 | -809 |
| Net income to common shareholders | -300 | -172 | 4,349 | -1,009 | — | — |
| Basic EPS | -0.43 | -0.24 | 5.55 | -1.42 | -1.26 | — |
| Diluted EPS | -0.54 | -0.24 | 5.23 | -1.42 | -1.26 | — |
| Average shares (basic) | 694 | 725 | 783 | 713 | — | — |
| Average shares (diluted) | 694 | 725 | 831 | 713 | 670 | — |